Catherine H Smith
Overview
Explore the profile of Catherine H Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
4071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phan D, Bewley A, Laws P, Mackenzie T, Smith C, Griffiths C, et al.
JAMA Dermatol
. 2025 Mar;
PMID: 40042863
Importance: The uncertainties about the real-world effectiveness of adalimumab biosimilars limit their widespread adoption for psoriasis. Objective: To compare the effectiveness of adalimumab biosimilars Amjevita and Imraldi with Humira for...
2.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
Nat Commun
. 2025 Feb;
16(1):2051.
PMID: 40021644
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
3.
Kroah-Hartman M, Lee J, Dooley N, Tan W, Mineur M, Paolino A, et al.
Br J Dermatol
. 2025 Feb;
PMID: 39999378
No abstract available.
4.
Schwarz C, Blegvad C, Baudry D, Tosi I, Lee S, Chung R, et al.
J Invest Dermatol
. 2025 Feb;
PMID: 39983980
No abstract available.
5.
Thomas C, Baudry D, Arkir Z, Coker B, Dasandi T, Powell K, et al.
J Invest Dermatol
. 2025 Feb;
PMID: 39983977
An increasing number of individuals receiving psoriasis biologics achieve clear/nearly clear skin (disease control). Clinical trial data indicate that some maintain disease control with lower doses, especially those with higher...
6.
Alabas O, Mason K, Yiu Z, Smith C, Warren R, Grifths C
Br J Dermatol
. 2025 Jan;
PMID: 39792925
Background: The current management of psoriasis does not differentiate between young and old patients in selecting the safest and/or most effective biologic. Objectives: To explore the effect of age at...
7.
Ramessur R, Saklatvala J, Budu-Aggrey A, Ostaszewski M, Mobus L, Greco D, et al.
JAMA Cardiol
. 2024 Sep;
9(11):1009-1017.
PMID: 39292496
Importance: The epidemiological link between immune-mediated diseases (IMIDs) and cardiovascular disease has often been attributed to systemic inflammation. However, the direction of causality and the biological mechanisms linking cardiovascular disease...
8.
Hernandez-Cordero A, Thomas L, Smail A, Lim Z, Saklatvala J, Chung R, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):657-665.e9.
PMID: 38815935
Background: Palmoplantar pustulosis (PPP) is an inflammatory skin disorder that mostly affects smokers and manifests with painful pustular eruptions on the palms and soles. Although the disease can present with...
9.
Francis L, Capon F, Smith C, Haniffa M, Mahil S
J Allergy Clin Immunol
. 2024 May;
154(1):42-50.
PMID: 38761994
The routine use of targeted systemic immunomodulatory therapies has transformed outcomes for people with severe psoriasis, with skin clearance (clinical remission) rates up to 60% at 1 year of biologic...
10.
OReilly M, Paolino A, Pathmarajah P, Ferguson J, Smith C, Sarkany R, et al.
Br J Dermatol
. 2024 Apr;
191(2):297-299.
PMID: 38656979
No abstract available.